Glucocorticoid receptor-dependent immunomodulatory effect of ursodeoxycholic acid on liver lymphocytes in mice

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 305, Issue 6, 2013, Pages

  Takigawa, Toshimichi ^a   Miyazaki, Hiromi ^a   Kinoshita, Manabu ^a   Kawarabayashi, Nobuaki ^a   Nishiyama, Kiyoshi ^a   Hatsuse, Kazuo ^a   Ono, Satoshi ^a   Saitoh, Daizoh ^a   Seki, Shuhji ^a   Yamamoto, Junji ^a  

^a NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

Author keywords

Concanavalin A; Escherichia coli; IFN ; LPS; RU486

Indexed keywords

BILE ACID; GLUCOCORTICOID RECEPTOR; GRANZYME; INTERLEUKIN 18; PERFORIN; URSODEOXYCHOLIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOIMMUNE HEPATITIS; BACTERIAL INFECTION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; IMMUNOMODULATION; KUPFFER CELL; LIVER; LIVER CELL; LYMPHOCYTE; MALE; MONONUCLEAR CELL; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SEPTIC SHOCK;

CONCANAVALIN-A; ESCHERICHIA COLI; IFN-Γ; LPS; RU486;

ANIMALS; CELLS, CULTURED; CONCANAVALIN A; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; HEPATITIS, ANIMAL; HEPATOCYTES; IMMUNOLOGIC FACTORS; INTERLEUKIN-18; KUPFFER CELLS; LIPOPOLYSACCHARIDES; LIVER; LYMPHOCYTES; MICE; MICE, INBRED C57BL; RECEPTORS, GLUCOCORTICOID; SHOCK, SEPTIC; TRANSCRIPTION, GENETIC; URSODEOXYCHOLIC ACID;

EID: 84884366833     PISSN: 01931857     EISSN: 15221547     Source Type: Journal    
DOI: 10.1152/ajpgi.00205.2012     Document Type: Article

References (49)

1. Alpini G, Glaser SS, Ueno Y, Rodgers R, Phinizy JL, Francis H, Baiocchi L, Holcomb LA, Caligiuri A, LeSage GD. Bile acid feeding induces cholangiocyte proliferation and secretion: evidence for bile acidregulated ductal secretion. Gastroenterology 116: 179-186, 1999.
2. Amaral JD, Viana RJ, Ramalho RM, Steer CJ, Rodrigues CM. Bile acids: regulation of apoptosis by ursodeoxycholic acid. J Lipid Res 50: 1721-1734, 2009.
3. Ami K, Kinoshita M, Yamauchi A, Nishikage T, Habu Y, Shinomiya N, Iwai T, Hiraide H, Seki S. IFN-gamma production from liver mononuclear cells of mice in burn injury as well as in postburn bacterial infection models and the therapeutic effect of IL-18. J Immunol 169: 4437-4442, 2002.
4. Annane D, Cavaillon JM. Corticosteroids in sepsis: from bench to bedside? Shock 20: 197-207, 2003.
5. Beato M, Herrlich P, Schutz G. Steroid hormone receptors: many actors in search of a plot. Cell 83: 851-857, 1995.
6. Beuers U. Drug insight: mechanisms and sites of action of ursodeoxycholic acid in cholestasis. Nat Clin Pract Gastroenterol Hepatol 3: 318-328, 2006.
7. Bornstein SR. Predisposing factors for adrenal insufficiency. N Engl J Med 360: 2328-2339, 2009.
8. Byrne AM, Foran E, Sharma R, Davies A, Mahon C, O'Sullivan J, O'Donoghue D, Kelleher D, Long A. Bile acids modulate the Golgi membrane fission process via a protein kinase Ceta and protein kinase D-dependent pathway in colonic epithelial cells. Carcinogenesis 31: 737-744, 2010.
9. Calmus Y, Weill B, Ozier Y, Chereau C, Houssin D, Poupon R. Immunosuppressive properties of chenodeoxycholic and ursodeoxycholic acids in the mouse. Gastroenterology 103: 617-621, 1992.
10. Das M, Sabio G, Jiang F, Rincon M, Flavell RA, Davis RJ. Induction of hepatitis by JNK-mediated expression of TNF-alpha. Cell 136: 249-260, 2009.
11. Efficacy and indications of ursodeoxycholic acid treatment for dissolving gallstones. A multicenter double-blind trial. Tokyo Cooperative Gallstone Study Group. Gastroenterology 78: 542-548, 1980.
12. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol 51: 237-267, 2009.
13. Evans RM. The steroid and thyroid hormone receptor superfamily. Science 240: 889-895, 1988.
14. Fickert P, Zollner G, Fuchsbichler A, Stumptner C, Pojer C, Zenz R, Lammert F, Stieger B, Meier PJ, Zatloukal K, Denk H, Trauner M. Effects of ursodeoxycholic and cholic acid feeding on hepatocellular transporter expression in mouse liver. Gastroenterology 121: 170-183, 2001.
15. Gershwin ME, Ansari AA, Mackay IR, Nakanuma Y, Nishio A, Rowley MJ, Coppel RL. Primary biliary cirrhosis: an orchestrated immune response against epithelial cells. Immunol Rev 174: 210-225, 2000.
16. Glass CK, Ogawa S. Combinatorial roles of nuclear receptors in inflammation and immunity. Nat Rev Immunol 6: 44-55, 2006.
17. Goodwin B, Kliewer SA. Nuclear receptors. I. Nuclear receptors and bile acid homeostasis. Am J Physiol Gastrointest Liver Physiol 282: G926-G931, 2002.
18. Inatsu A, Kinoshita M, Nakashima H, Shimizu J, Saitoh D, Tamai S, Seki S. Novel mechanism of C-reactive protein for enhancing mouse liver innate immunity. Hepatology 49: 2044-2054, 2009.
19. Ishizaki K, Iwaki T, Kinoshita S, Koyama M, Fukunari A, Tanaka H, Tsurufuji M, Sakata K, Maeda Y, Imada T, Chiba K. Ursodeoxycholic acid protects concanavalin A-induced mouse liver injury through inhibition of intrahepatic tumor necrosis factor-alpha and macrophage inflammatory protein-2 production. Eur J Pharmacol 578: 57-64, 2008.
20. Iwaki T, Ishizaki K, Kinoshita S, Tanaka H, Fukunari A, Tsurufuji M, Imada T. Protective effects of ursodeoxycholic acid on chenodeoxycholic acid-induced liver injury in hamsters. World J Gastroenterol 13: 5003-5008, 2007.
21. Kawarabayashi N, Seki S, Hatsuse K, Kinoshita M, Takigawa T, Tsujimoto H, Kawabata T, Nakashima H, Shono S, Mochizuki H. Immunosuppression in the livers of mice with obstructive jaundice participates in their susceptibility to bacterial infection and tumor metastasis. Shock 33: 500-506, 2010.
22. Kinoshita M, Seki S, Ono S, Shinomiya N, Hiraide H. Paradoxical effect of IL-18 therapy on the severe and mild Escherichia coli infections in burn-injured mice. Ann Surg 240: 313-320, 2004.
23. Kinoshita M, Uchida T, Nakashima H, Ono S, Seki S, Hiraide H. Opposite effects of enhanced tumor necrosis factor-alpha production from Kupffer cells by gadolinium chloride on liver injury/mortality in endotoxemia of normal and partially hepatectomized mice. Shock 23: 65-72, 2005.
24. Kohno H, Suzuki R, Yasui Y, Miyamoto S, Wakabayashi K, Tanaka T. Ursodeoxycholic acid versus sulfasalazine in colitis-related colon carcinogenesis in mice. Clin Cancer Res 13: 2519-2525, 2007.
25. Krahenbuhl S, Fischer S, Talos C, Reichen J. Ursodeoxycholate protects oxidative mitochondrial metabolism from bile acid toxicity: doseresponse study in isolated rat liver mitochondria. Hepatology 20: 1595-1601, 1994.
26. Lazaridis KN, Gores GJ, Lindor KD. Ursodeoxycholic acid 'mechanisms of action and clinical use in hepatobiliary disorders.' J Hepatol 35: 134-146, 2001.
27. Leevy CB, Holt J Jr, Buniak B. Immunologic effects of ursodeoxycholic acid in primary biliary cirrhosis. J Assoc Acad Minor Phys 4: 30-32, 1993.
28. Makishima M, Okamoto AY, Repa JJ, Tu H, Learned RM, Luk A, Hull MV, Lustig KD, Mangelsdorf DJ, Shan B. Identification of a nuclear receptor for bile acids. Science 284: 1362-1365, 1999.
29. Mitchell SA, Bansi DS, Hunt N, Von Bergmann K, Fleming KA, Chapman RW. A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis. Gastroenterology 121: 900-907, 2001.
30. Motegi A, Kinoshita M, Inatsu A, Habu Y, Saitoh D, Seki S. IL-15-induced CD8+CD122+ T cells increase antibacterial and anti-tumor immune responses: implications for immune function in aged mice. J Leukoc Biol 84: 1047-1056, 2008.
31. Nakashima H, Kinoshita M, Nakashima M, Habu Y, Shono S, Uchida T, Shinomiya N, Seki S. Superoxide produced by Kupffer cells is an essential effector in concanavalin A-induced hepatitis in mice. Hepatology 48: 1979-1988, 2008.
32. Okamura H, Tsutsi H, Komatsu T, Yutsudo M, Hakura A, Tanimoto T, Torigoe K, Okura T, Nukada Y, Hattori K, Akita K, Namba M, Tanabe F, Konishi K, Fukuda S, Kurimoto M. Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature 378: 88-91, 1995.
33. Omata M, Yoshida H, Toyota J, Tomita E, Nishiguchi S, Hayashi N, Iino S, Makino I, Okita K, Toda G, Tanikawa K, Kumada H. A large-scale, multicentre, double-blind trial of ursodeoxycholic acid in patients with chronic hepatitis C. Gut 56: 1747-1753, 2007.
34. Parks DJ, Blanchard SG, Bledsoe RK, Chandra G, Consler TG, Kliewer SA, Stimmel JB, Willson TM, Zavacki AM, Moore DD, Lehmann JM. Bile acids: natural ligands for an orphan nuclear receptor. Science 284: 1365-1368, 1999.
35. Paumgartner G, Beuers U. Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited. Hepatology 36: 525-531, 2002.
36. Poupon RE, Balkau B, Eschwege E, Poupon R. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group. N Engl J Med 324: 1548-1554, 1991.
37. Sato K, Kinoshita M, Motegi A, Habu Y, Takayama E, Nonoyama S, Hiraide H, Seki S. Critical role of the liver CD8+ CD122+ T cells in the generalized Shwartzman reaction of mice. Eur J Immunol 35: 593-602, 2005.
38. Schuetz EG, Strom S, Yasuda K, Lecureur V, Assem M, Brimer C, Lamba J, Kim RB, Ramachandran V, Komoroski BJ, Venkataramanan R, Cai H, Sinal CJ, Gonzalez FJ, Schuetz JD. Disrupted bile acid homeostasis reveals an unexpected interaction among nuclear hormone receptors, transporters, and cytochrome P450. J Biol Chem 276: 39411-39418, 2001.
39. Seki S, Habu Y, Kawamura T, Takeda K, Dobashi H, Ohkawa T, Hiraide H. The liver as a crucial organ in the first line of host defense: the roles of Kupffer cells, natural killer (NK) cells and NK1.1 Ag+ T cells in T helper 1 immune responses. Immunol Rev 174: 35-46, 2000.
40. Serviddio G, Pereda J, Pallardo FV, Carretero J, Borras C, Cutrin J, Vendemiale G, Poli G, Vina J, Sastre J. Ursodeoxycholic acid protects against secondary biliary cirrhosis in rats by preventing mitochondrial oxidative stress. Hepatology 39: 711-720, 2004.
41. Sola S, Amaral JD, Castro RE, Ramalho RM, Borralho PM, Kren BT, Tanaka H, Steer CJ, Rodrigues CM. Nuclear translocation of UDCA by the glucocorticoid receptor is required to reduce TGF-beta1-induced apoptosis in rat hepatocytes. Hepatology 42: 925-934, 2005.
42. Staudinger JL, Goodwin B, Jones SA, Hawkins-Brown D, MacKenzie KI, LaTour A, Liu Y, Klaassen CD, Brown KK, Reinhard J, Willson TM, Koller BH, Kliewer SA. The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity. Proc Natl Acad Sci USA 98: 3369-3374, 2001.
43. Takano S, Ito Y, Yokosuka O, Ohto M, Uchiumi K, Hirota K, Omata M. A multicenter randomized controlled dose study of ursodeoxycholic acid for chronic hepatitis C. Hepatology 20: 558-564, 1994.
44. Tiegs G, Hentschel J, Wendel A. A T cell-dependent experimental liver injury in mice inducible by concanavalin A. J Clin Invest 90: 196-203, 1992.
45. Visser J, van Boxel-Dezaire A, Methorst D, Brunt T, de Kloet ER, Nagelkerken L. Differential regulation of interleukin-10 (IL-10) and IL-12 by glucocorticoids in vitro. Blood 91: 4255-4264, 1998.
46. Weitzel C, Stark D, Kullmann F, Scholmerich J, Holstege A, Falk W. Ursodeoxycholic acid induced activation of the glucocorticoid receptor in primary rat hepatocytes. Eur J Gastroenterol Hepatol 17: 169-177, 2005.
47. Xie W, Radominska-Pandya A, Shi Y, Simon CM, Nelson MC, Ong ES, Waxman DJ, Evans RM. An essential role for nuclear receptors SXR/PXR in detoxification of cholestatic bile acids. Proc Natl Acad Sci USA 98: 3375-3380, 2001.
48. Yoshikawa M, Tsujii T, Matsumura K, Yamao J, Matsumura Y, Kubo R, Fukui H, Ishizaka S. Immunomodulatory effects of ursodeoxycholic acid on immune responses. Hepatology 16: 358-364, 1992.
49. Zhang Y, Klaassen CD. Effects of feeding bile acids and a bile acid sequestrant on hepatic bile acid composition in mice. J Lipid Res 51: 3230-3242, 2010.